Literature DB >> 15196167

Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma.

J Gutermuth1, H Audring, C Voit, U Trefzer, N Haas.   

Abstract

BACKGROUND: Eccrine porocarcinoma (EP) is a rare malignant tumour arising in the acrosyringium, with about 50% of the cases developing local recurrence or metastatic disease. No standard therapy protocols for metastatic disease exist. In the past, only short remissions were achieved by applying combinations of cytotoxic agents, which were associated with severe side-effects. AIM OF THE STUDY: In the case reported here, the aim was to find a protocol with fewer side-effects for a patient who was not willing to undergo extensive polychemotherapy. SUBJECT: A 67-year-old male patient with local recurrence and regional lymph node metastases after resection of EP was treated with a combination of interferon-alpha (IFN-alpha) 9 million units s.c. three times per week and paclitaxel 100 mg/m(2) weekly i.v., which shows a side-effect profile similar to taxotere and is used in the treatment of a variety of neoplasms such as advanced squamous cell carcinoma. MAIN OUTCOME: This less aggressive treatment was tolerated well and the patient responded with minor remission and long-term stable disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196167     DOI: 10.1111/j.1468-3083.2004.00949.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  8 in total

Review 1.  Current Treatment Options for Cutaneous Adnexal Malignancies.

Authors:  Hiroyuki Goto
Journal:  Curr Treat Options Oncol       Date:  2022-03-26

2.  A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.

Authors:  Bhuvaneswari Ramaswamy; Tanios Bekaii-Saab; Larry J Schaaf; Gregory B Lesinski; David M Lucas; Donn C Young; Amy S Ruppert; John C Byrd; Kristy Culler; Diedre Wilkins; John J Wright; Michael R Grever; Charles L Shapiro
Journal:  Cancer Chemother Pharmacol       Date:  2009-09-23       Impact factor: 3.333

3.  Eccrine porocarcinoma (malignant eccrine poroma): a series of eight challenging cases.

Authors:  Murilo de Almeida Luz; Daniel Cury Ogata; Marcos Flávio Gomes Montenegro; Luciano José Biasi; Leandro Carvalho Ribeiro
Journal:  Clinics (Sao Paulo)       Date:  2010-07       Impact factor: 2.365

4.  Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.

Authors:  Long P Le; Dora Dias-Santagata; Amanda C Pawlak; Arjola K Cosper; Anh Thu Nguyen; M Angelica Selim; April Deng; Nora K Horick; A John Iafrate; Martin C Mihm; Mai P Hoang
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

5.  Metastatic Eccrine Porocarcinoma: A Rare Case of Successful Treatment.

Authors:  Hiren Mandaliya; Ina Nordman
Journal:  Case Rep Oncol       Date:  2016-08-17

Review 6.  Intergluteal Cleft Eccrine Porocarcinoma with Metastasis to Inguinal Region and Lung: Case Report and Review of the Literature.

Authors:  Ricardo Fernández-Ferreira; Gabriela Alvarado-Luna; Daniel Motola-Kuba; Ileana Mackinney-Novelo; Eduardo Emir Cervera-Ceballos; Román Segura-Rivera
Journal:  Case Rep Oncol       Date:  2020-12-10

Review 7.  Porocarcinoma; presentation and management, a meta-analysis of 453 cases.

Authors:  Abdulwahid M Salih; F H Kakamad; Hiwa O Baba; Rawezh Q Salih; M R Hawbash; Shvan H Mohammed; Snur Othman; Yadgar A Saeed; Imad J Habibullah; Aso S Muhialdeen; Rebaz O Nawroly; Zuhair D Hammood; Nawshirwan H Abdulkarim
Journal:  Ann Med Surg (Lond)       Date:  2017-06-20

8.  Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.

Authors:  Regina C Betz; Silke Redler; Evgeniya Denisova; Dana Westphal; Harald M Surowy; Friedegund Meier; Barbara Hutter; Julia Reifenberger; Arno Rütten; Alexander Schulz; Mildred Sergon; Mirjana Ziemer; Benedikt Brors
Journal:  Cancer Gene Ther       Date:  2021-05-27       Impact factor: 5.854

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.